Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Study of Men Born in 1943

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03138122
Recruitment Status : Active, not recruiting
First Posted : May 3, 2017
Last Update Posted : April 4, 2019
Sponsor:
Information provided by (Responsible Party):
Per-Olof Hansson, Sahlgrenska University Hospital, Sweden

Brief Summary:
A random sample a random sample of half of all men born in 1943 and living in the city of Gothenburg, Sweden, have been investigated in 1993 at 50 years of age and will be followed continuously with repeated re-examinations and follow-up concerning mortality and cardiovascular diseased. Out of 1463 invited men, 798 (54.5%) accepted the invitation and is included in this longitudinal cohort study.

Condition or disease
Cardiovascular Risk Factor Atrial Fibrillation Congestive Heart Failure Sleep Apnea Cardiovascular Diseases

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 798 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Study of Men Born in 1943 - A Longitudinal Cohort Study From Middle-Age and Onward
Actual Study Start Date : February 9, 1993
Estimated Primary Completion Date : December 31, 2043
Estimated Study Completion Date : December 31, 2043

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Cardiovascular diseases [ Time Frame: from date of first examination until the date of endpoint or date of death from any cause, whichever come first assessed up to 20, 30, 40 and 50 years ]
    Alla major cardiovascular events including cardiovascular death, myocardial Infarction, congestive heart failure atrial fibrillation, stroke and venous thromboembolism


Secondary Outcome Measures :
  1. Sleep apnoea syndrome [ Time Frame: at 71 years of age ]
    Apnoea and hypopnoea as well as desaturation defined according to guide lines for scoring sleep apnoea.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
A random population sample consisting half of all men born in 1943 and living in the city of Gothenburg, Sweden was invited. . Out of 1463 invited men, 798 (54.5%) accepted participation.
Criteria

Inclusion Criteria:

  • Men born in 1943 and living in the city of Gothenburg, Sweden

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03138122


Locations
Layout table for location information
Sweden
Sahlgrenska University Hospital / Östra
Gothenburg, Västra Götaland Region, Sweden, 416 85
Sponsors and Collaborators
Sahlgrenska University Hospital, Sweden

Layout table for additonal information
Responsible Party: Per-Olof Hansson, M.D, Ph.D.,, Sahlgrenska University Hospital, Sweden
ClinicalTrials.gov Identifier: NCT03138122    
Other Study ID Numbers: SahlgrenskaUH/Östra
First Posted: May 3, 2017    Key Record Dates
Last Update Posted: April 4, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Atrial Fibrillation
Cardiovascular Diseases
Heart Diseases
Arrhythmias, Cardiac
Pathologic Processes